National Park Medical Center is proud to offer bamlanivimab and etesevimab/casirivimab and imdevimab therapy, a monoclonal antibody treatment for eligible positive COVID-19 patients.
What is bamlanivimab and etesevimab/casirivimab and imdevimab or monoclonal antibody treatment?
Bamlanivimab and etesevimab/Casirivimab and imdevimab is a monoclonal antibody therapy to help treat non-hospitalized patients with a mild or moderate case of COVID-19 (SARS-CoV-2). Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful viruses. This therapy is designed to help block the COVID-19 virus and prevent the virus from further infecting healthy cells.
Bamlanivimab and etesevimab/Casirivimab and imdevimab have received emergency use authorization (EUA) from the Food and Drug Administration (FDA).
Who is a candidate for monoclonal antibody treatment?
Adults and adolescents 12 years of age or older with mild to moderate symptoms who weigh 88 pounds (40 kg) or more, and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization.
Who is not a candidate for this treatment?
This treatment WILL NOT be considered for patients who are currently hospitalized due to COVID-19, require oxygen therapy for COVID-19, and/or have a known hypersensitivity to bamlanivimab and etesevimab/ casirivimab and imdevimab.
How do I qualify for this treatment?
This therapy requires an order from a healthcare provider.
Contact your primary care physician (PCP) to make an appointment, OR
Call our Provider Referral Line (PRL) at 877-320-3222 or visit our Find a Provider feature.
What should I expect?
Your physician’s office will provide steps on how and where you will be receiving your treatment. Treatment is administered either by intravenous route (using IV therapy) or by subcutaneous injections. Patients receiving treatment at NPMC will be required to stay for a duration of up to 2 hours.
Important facts about bamlanivimab and etesevimab
For information on the authorized use of bamlanivimab and etesevimab and mandatory requirements under the Emergency Use Authorization, please review:
Important facts about casirivimab and imdevimab
For information on the authorized use of casirivimab and imdevimab and mandatory requirements under the Emergency Use Authorization, please review:
Fact Sheet for Patients, Parents and Caregivers (English)
Fact Sheet for Patients Parents and Caregivers (Spanish)